Checkpoint Therapeutics’ (CKPT) “Buy” Rating Reiterated at HC Wainwright

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 395.05% from the stock’s previous close.

Checkpoint Therapeutics Stock Performance

NASDAQ CKPT opened at $4.04 on Wednesday. Checkpoint Therapeutics has a fifty-two week low of $1.36 and a fifty-two week high of $4.50. The firm has a market capitalization of $197.27 million, a P/E ratio of -2.20 and a beta of 1.34. The stock has a 50-day simple moving average of $3.20 and a two-hundred day simple moving average of $2.55.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). As a group, analysts forecast that Checkpoint Therapeutics will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CKPT. Vanguard Group Inc. increased its holdings in Checkpoint Therapeutics by 67.4% in the first quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock valued at $1,882,000 after buying an additional 369,586 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in Checkpoint Therapeutics by 366.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after buying an additional 180,050 shares in the last quarter. PVG Asset Management Corp purchased a new position in Checkpoint Therapeutics in the second quarter valued at $295,000. Geode Capital Management LLC increased its holdings in Checkpoint Therapeutics by 41.2% in the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after buying an additional 124,787 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in Checkpoint Therapeutics by 160.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after buying an additional 80,000 shares in the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.